You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Colorcon
Boehringer Ingelheim
McKinsey
Dow

Last Updated: November 26, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FLIBANSERIN

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Flibanserin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00277914 Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women Completed Sprout Pharmaceuticals, Inc Phase 3 2006-01-01 To estimate the duration of efficacy with continued treatment of double-blind flibanserin or placebo over twenty-four weeks of treatment.
NCT00360243 6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA Completed Sprout Pharmaceuticals, Inc Phase 3 2006-07-01 This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meet standard diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group.
NCT00360529 24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder Completed Sprout Pharmaceuticals, Inc Phase 3 2006-07-01 This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group.
NCT00360555 Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder Completed Sprout Pharmaceuticals, Inc Phase 3 2006-07-01 This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group.
NCT00441558 A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD). Terminated Sprout Pharmaceuticals, Inc Phase 3 2007-02-01 To determine if long-term treatment with Flibanserin is safe and to monitor the effectiveness of Flibanserin in Women with HSDD that have already completed a previous study (511.70/71/.74/.75/.105) with Flibanserin.
NCT00491829 Flibanserin Versus Placebo in Premenopausal Women With HSDD Completed Sprout Pharmaceuticals, Inc Phase 3 2007-06-01 To establish efficacy of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in 6-month treatment, vs placebo for Hypoactive Sexual Desire Disorder in premenopausal European women. To evaluate safety and tolerability of flibanserin in such patients.
NCT00601367 Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder Completed Sprout Pharmaceuticals, Inc Phase 3 2008-01-01 Safety profile of flibanserin over 28 additional weeks Distribution of preferred dose regimens
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Flibanserin

Condition Name

Condition Name for Flibanserin
Intervention Trials
Sexual Dysfunctions, Psychological 13
Hypoactive Sexual Desire Disorder 2
Healthy 2
Low Libido 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Flibanserin
Intervention Trials
Sexual Dysfunctions, Psychological 16
Hypokinesia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Flibanserin

Trials by Country

Trials by Country for Flibanserin
Location Trials
United States 310
Canada 44
Germany 3
United Kingdom 2
Czech Republic 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Flibanserin
Location Trials
Illinois 11
Tennessee 11
Florida 11
California 11
Texas 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Flibanserin

Clinical Trial Phase

Clinical Trial Phase for Flibanserin
Clinical Trial Phase Trials
Phase 4 1
Phase 3 12
Phase 2 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Flibanserin
Clinical Trial Phase Trials
Completed 11
Terminated 4
Not yet recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Flibanserin

Sponsor Name

Sponsor Name for Flibanserin
Sponsor Trials
Sprout Pharmaceuticals, Inc 14
San Diego Sexual Medicine 1
Boehringer Ingelheim 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Flibanserin
Sponsor Trials
Industry 16
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Baxter
McKinsey
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.